Queen Mary University of London
London, United Kingdom
John Snow Professor of Epidemiology
Improving accuracy of predicting breast cancer risk and enhancing our understanding of preventative therapy.
Analysis of biobanked samples—blood, tissue, and clinical data from consenting patients—is critical for cancer research. Mountains of data can be gleaned from biobanks, and Drs. Cuzick and Francis and their teams are pioneers in leveraging the biobanked data to expand our understanding of breast cancer prevention. Their studies may assist with the development of personalized treatments.
The High-Risk Breast Cancer Bio-bank (HRBCBB) was established with biospecimens and mammograms from women in the IBIS-I, IBIS-II, IBIS-II DCIS, and LATER clinical trials. Through the years, additional biospecimens from further clinical trials in early breast cancer (NeoGem, ELIMINATE, NeoN, CHARIOT, EXPERT) or metastatic breast cancer (DIAmOND, CAPTURE) and the UK/ANZ DCIS trial have been collected and added to the HRBCBB Bio-bank.
Prevention research is a long-term game as it takes many years of follow-up to ensure that preventive measures are effective. In the coming year, the team will continue to add digitized data from several ongoing and imminent clinical trials to their databank to further explore correlative factors including patient hormone levels and prognostic biological indicators using new artificial intelligence-based technologies.
Jack Cuzick, PhD is the John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York.
His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumors as an indicator of its potential chemopreventive role and has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behavior of early prostate cancer.
Dr. Cuzick is a Fellow of the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics, the Royal Society, and an Honorary Fellow of the Royal College of Physicians and was awarded a CBE by the Queen in 2017. In 2007, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science and this has been re-awarded for several years thereafter. He was awarded the AACR Cancer Prevention Prize in 2012. He is the author of more than 650 peer-reviewed papers and has published in all the major medical journals.
The Delta Air Lines Award
University of Melbourne
Please remember BCRF in your will planning. Learn More
Breast Cancer Research Foundation28 West 44th Street, Suite 609, New York, NY 10036
General Office: 646-497-2600 | Toll Free: email@example.com | BCRF is a 501 (c)(3) | EIN: 13-3727250